Aminoglycoside antibiotics are the class most strongly linked to permanent hearing loss, but they are not the only antibiotics that can damage your ears. Macrolides, vancomycin, capreomycin, and even certain fluoroquinolones have all been associated with ototoxicity to varying degrees. The risk, the type of damage, and whether it reverses depend heavily on the specific drug, the dose, how long you take it, and a handful of personal risk factors that most people never think about until the ringing starts.
Aminoglycosides Are the Primary Offenders
When clinicians talk about antibiotic ototoxicity, they almost always mean aminoglycosides first. This class includes gentamicin, streptomycin, amikacin, tobramycin, and netilmicin. These drugs are used for serious gram-negative infections and tuberculosis, and they are highly effective, but they carry a well-documented risk of damaging the inner ear. Aminoglycosides target the outer hair cells in the base of the cochlea, the region responsible for detecting high-pitched sounds, and they destroy those cells through a cascade that begins with the buildup of toxic molecules called reactive oxygen species.1Kidney International. Minireview Ototoxicity Because those hair cells do not regenerate in humans, the hearing loss is permanent once it sets in.
One large prospective study that tracked hospitalized patients receiving aminoglycosides found hearing loss in nearly half of the ears monitored, with the damage first appearing in high-frequency ranges above what standard hearing tests typically check.2The Journal of Infectious Diseases. High-Frequency Audiometric Monitoring for Early Detection of Aminoglycoside Ototoxicity That high-frequency pattern is a hallmark of aminoglycoside damage and explains why many patients do not notice a problem at first. You might lose the ability to hear a bird’s call or a smoke alarm before you have trouble following a conversation.
Not all aminoglycosides are equally damaging, and some lean more toward harming hearing while others preferentially damage the vestibular system, the part of the inner ear responsible for balance. In animal studies comparing several aminoglycosides, streptomycin caused the most severe vestibular damage, followed by gentamicin, amikacin, and netilmicin in decreasing order of severity.3Yonsei Medical Journal. Comparative Vestibulotoxicity of Different Aminoglycosides in the Guinea Pigs Gentamicin is sometimes described as predominantly vestibulotoxic (causing dizziness and balance problems), while amikacin and neomycin are more often associated with cochleotoxicity (hearing loss). In practice, many patients experience both to some degree.
How Aminoglycosides Get into the Inner Ear
The inner ear is normally shielded from the bloodstream by a barrier similar to the blood-brain barrier. Aminoglycosides manage to cross this barrier and enter the fluid-filled chambers of the cochlea, where they are taken up by hair cells.4PubMed Central. Intra-cochlear trafficking of aminoglycosides Once inside, the drugs accumulate. Unlike most tissues that clear aminoglycosides within hours, the inner ear holds onto them for weeks or even months. This is why hearing loss can appear days or weeks after a course of aminoglycosides has ended, catching patients and clinicians off guard.
Inside hair cells, aminoglycosides trigger the production of reactive oxygen species, which overwhelm the cell’s built-in antioxidant defenses and set off a chain of events leading to cell death.1Kidney International. Minireview Ototoxicity The outer hair cells at the base of the cochlea are hit first and hardest, which is why high-frequency hearing goes first. If exposure continues, the damage creeps toward the apex of the cochlea, progressively affecting lower and lower frequencies until conversational speech becomes difficult to hear.
Macrolides and Hearing
Macrolide antibiotics, including erythromycin, azithromycin, and clarithromycin, are among the most commonly prescribed antibiotics in the world. Their association with ototoxicity is real but substantially different from aminoglycosides. Macrolide-related hearing problems tend to appear at high doses, resolve after the drug is stopped, and more often take the form of tinnitus than measurable hearing loss.
A large cross-sectional and longitudinal study found that people who had ever used macrolides had a roughly 25% higher likelihood of experiencing tinnitus compared with non-users. The association was stronger with higher cumulative doses and with intermediate- or long-acting macrolides. Users between two study time points had more than double the risk of developing new-onset tinnitus. Interestingly, the study found no general association between macrolide use and actual hearing loss, though a borderline effect on hearing thresholds was noted in very recent users within about three weeks of taking the drug.5PubMed Central. Macrolide-associated ototoxicity: a cross-sectional and longitudinal study to assess the association of macrolide use with tinnitus and hearing loss
Most macrolide-associated hearing changes reverse once the drug is discontinued, but rare exceptions exist. Case reports have documented irreversible sensorineural hearing loss after azithromycin, typically in patients receiving prolonged high-dose therapy for serious conditions like AIDS-related infections.6PubMed. Irreversible sensorineural hearing loss as a result of azithromycin ototoxicity. A case report For the average person prescribed a five-day course of azithromycin for a sinus infection, the risk of lasting hearing damage is extremely small. The concern grows with higher doses and longer durations.
Vancomycin and Other Glycopeptides
Vancomycin, a glycopeptide antibiotic used against serious gram-positive infections like MRSA, has been debated for decades as a potential cause of hearing loss. The picture that has emerged is complicated. Vancomycin probably does carry some ototoxic risk, but it is lower than aminoglycosides and appears concentrated in specific patient groups.
A study of 89 patients receiving vancomycin for an average of 27 days found a 12% rate of high-frequency hearing loss overall. But the age breakdown told a more revealing story: patients under 53 had a 0% rate, while patients over 53 had a 19% rate.7PubMed Central. Vancomycin ototoxicity: a reevaluation in an era of increasing doses A separate study of patients on long-term intravenous vancomycin found that only about 8% experienced a worsening change in hearing, and no variables tested, including high serum drug levels or doses of four grams per day or more, were significantly associated with the change.8PubMed Central. Long-term vancomycin use had low risk of ototoxicity
In pediatric patients who received accidental vancomycin overdoses, transient ototoxicity was found in one patient, but prolonged hearing loss was not observed in any of the cases studied.9PubMed Central. Ototoxicity and Nephrotoxicity With Elevated Serum Concentrations Following Vancomycin Overdose: A Retrospective Case Series The overall weight of evidence suggests vancomycin-related hearing damage is uncommon and that older adults face the most meaningful risk. Clinicians still monitor hearing in patients on extended vancomycin courses, especially when the drug is combined with aminoglycosides, a common pairing that raises the overall ototoxic potential.
Newer glycopeptides appear to be safer for hearing. In a Phase I trial of dalbavancin, a long-acting glycopeptide, audiologic monitoring showed no ototoxic changes in any subjects, and no false-positive results were obtained either.10Journal of the American Academy of Audiology. Audiologic Monitoring for Potential Ototoxicity in a Phase I Clinical Trial of a New Glycopeptide Antibiotic
Other Antibiotics Worth Knowing About
Capreomycin, a polypeptide antibiotic used against drug-resistant tuberculosis, has been associated with ototoxicity in much the same pattern as aminoglycosides. This matters because drug-resistant TB treatment regimens often run for months, and in resource-limited settings where capreomycin sees its heaviest use, routine hearing monitoring may not be available.
Fluoroquinolones, including ciprofloxacin and moxifloxacin, are not typically considered ototoxic, but scattered case reports link them to tinnitus. At least one documented case involved a patient who developed tinnitus after a five-day course of oral moxifloxacin for diverticulitis.11PubMed Central. Moxifloxacin-induced tinnitus in an older adult These events are rare enough that fluoroquinolones are not classified as ototoxic drugs in the way aminoglycosides or even macrolides are, but patients who experience new tinnitus while taking a fluoroquinolone should mention it to their prescriber.
Topical Ear Drops Can Be a Hidden Risk
Most people assume that ear drops are inherently safe because they are applied locally rather than injected or swallowed. For aminoglycoside-containing ear drops, that assumption breaks down when the eardrum is perforated. Health Canada has warned healthcare professionals about the risk of permanent hearing loss from gentamicin sulfate ear drops used in patients whose eardrums are not intact. When the tympanic membrane has a hole, the drops can migrate into the middle and inner ear, exposing those delicate structures directly to the drug.12PubMed Central. Ototoxic effects from gentamicin ear drops
This is relevant for people with chronic ear infections, ear tubes, or recent ear surgery, all situations in which the eardrum may not be intact. Non-aminoglycoside alternatives like ciprofloxacin-based ear drops do not carry the same cochleotoxic risk and are generally preferred when a perforation is present or suspected.
Why Some People Are Genetically Vulnerable
One of the more unsettling aspects of aminoglycoside ototoxicity is that certain people are genetically predisposed to hearing loss at doses that would be safe for most. The key culprit is a mutation in mitochondrial DNA called m.1555A>G, found in the gene encoding a component of the mitochondrial ribosome. This mutation causes the human mitochondrial ribosome to more closely resemble a bacterial ribosome, which is precisely the structure aminoglycosides are designed to attack. People carrying this mutation can experience severe hearing loss from even a single standard dose of an aminoglycoside.13PubMed Central. Mitochondrial DNA mutations associated with aminoglycoside induced ototoxicity
The m.1555A>G mutation is the most frequently identified genetic variant linked to aminoglycoside-induced hearing loss. A related mutation, m.1494C>T, operates through the same structural mechanism. Both alter the shape of the mitochondrial ribosome’s active site, increasing its binding affinity for aminoglycosides.14Egyptian Journal of Medical Human Genetics. Aminoglycoside induced ototoxicity associated with mitochondrial DNA mutations Nuclear modifier genes and mitochondrial haplotypes can also influence how severely the mutation manifests, which is one reason family members carrying the same mutation sometimes have different hearing outcomes.
What makes this genetic vulnerability tricky is that carriers often have perfectly normal hearing as long as they are never exposed to aminoglycosides. A population-based study of 44- to 45-year-olds carrying m.1555A>G found no significant difference in hearing thresholds compared with non-carriers at standard test frequencies, meaning the mutation alone, without aminoglycoside exposure, did not cause hearing loss by middle age.15BMJ Open. Hearing in 44–45 year olds with m.1555A>G, a genetic mutation predisposing to aminoglycoside-induced deafness: a population based cohort study The danger is specific to the drug-gene interaction. Genetic testing before aminoglycoside administration is increasingly discussed, and some hospitals have begun implementing rapid screening for this mutation, especially in neonatal units.
When Drugs Multiply Each Other’s Damage
Aminoglycoside ototoxicity gets worse when certain other drugs are on board. The best-documented combination is aminoglycosides paired with loop diuretics like furosemide, a drug used to remove excess fluid in patients with heart failure, kidney disease, or severe swelling. The interaction is not just additive; it is synergistic, meaning the combined damage far exceeds what either drug would cause alone.
The proposed mechanism involves a one-two punch. The aminoglycoside interacts with cell membranes in the inner ear and increases their permeability. The loop diuretic then penetrates the compromised cells in higher concentrations than it normally could, amplifying the damage.16PubMed. Ototoxicity induced by gentamicin and furosemide Animal research confirms this pattern: combining aminoglycosides with loop diuretics causes rapid, irreversible hair cell damage that far outpaces what either drug produces in isolation.17PubMed. Effects of combined gentamicin and furosemide treatment on cochlear ribbon synapses
Critically ill patients in intensive care units are the population most likely to receive both drug classes simultaneously: an aminoglycoside for a life-threatening infection and furosemide to manage fluid overload. If you or a family member is in this situation, it is worth asking whether the care team is aware of the combined ototoxic risk and whether hearing monitoring is in place.
What About Babies and Children?
Gentamicin is one of the most commonly administered antibiotics in neonatal intensive care units around the world, used to treat suspected sepsis in the first days of life. Given its known ototoxic potential, it is natural to worry about hearing outcomes in these vulnerable patients. The evidence so far is cautiously reassuring. A study evaluating gentamicin exposure in neonates found no association between gentamicin exposure variables and failed hearing screening tests in adjusted analyses.18PubMed Central. Evaluation of Gentamicin Exposure in the Neonatal Intensive Care Unit and Hearing Function at Discharge
Longer-term follow-up tells a similar story. A study of schoolchildren who had been exposed to a high-dose gentamicin regimen as neonates found that their hearing thresholds were within the normal range. After adjusting for birth weight, there was no difference between the gentamicin-exposed group and healthy controls.19Pediatrics. Hearing in Schoolchildren After Neonatal Exposure to a High-Dose Gentamicin Regimen The short courses typical of neonatal sepsis treatment, usually lasting just a few days, appear to carry substantially less risk than the prolonged courses used in adult tuberculosis or cystic fibrosis management. That said, the damage from aminoglycosides is permanent in children just as it is in adults, and hearing loss in a young child can affect speech and language development in ways that are harder to compensate for later.20PubMed Central. Aminoglycosides-Related Ototoxicity: Mechanisms, Risk Factors, and Prevention in Pediatric Patients
Monitoring and Early Detection
One of the most practical things you can do if you or a family member is prescribed an aminoglycoside is to ask about hearing monitoring. Standard hearing tests that check frequencies up to 8 kHz will miss early aminoglycoside damage, which typically begins above that range. Extended high-frequency audiometry, which tests up to 16 or 20 kHz, catches damage much earlier. In the prospective study of aminoglycoside-treated patients mentioned earlier, hearing loss first appeared in the high-frequency range in about 70% of affected ears. Testing only the most vulnerable five-frequency range above 8 kHz would have caught 82% of ears showing change at an early stage.2The Journal of Infectious Diseases. High-Frequency Audiometric Monitoring for Early Detection of Aminoglycoside Ototoxicity
Early detection matters because the most effective intervention is adjusting or stopping the drug before damage spreads to conversationally important frequencies. A baseline audiogram before treatment starts, followed by serial testing during therapy, gives clinicians a way to spot trouble before you notice anything wrong. Professional guidelines from audiology organizations outline specific criteria for what counts as an ototoxic change on a serial audiogram, providing a standardized trigger to reconsider the drug regimen.
Reducing the Risk Through Dosing and Drug Monitoring
The way aminoglycosides are dosed has shifted over the past few decades, partly in response to ototoxicity concerns. The traditional approach was to give smaller doses every eight or twelve hours. Research suggested that giving the entire daily dose as a single infusion once every 24 hours might reduce toxicity while maintaining or even improving effectiveness.21Journal of Hospital Infection. Single daily dose therapy with aminoglycosides A meta-analysis of 18 studies involving over 2,300 patients found that single daily dosing was more effective, less nephrotoxic, and roughly comparable in ototoxic risk to multiple daily doses.22American Journal of Health-System Pharmacy. Effectiveness and safety of once-daily aminoglycosides: A meta-analysis
For patients who need prolonged aminoglycoside therapy, such as those being treated for drug-resistant tuberculosis, therapeutic drug monitoring becomes especially important. A study at a tuberculosis center that used drug level monitoring to guide dosing found that hearing loss was limited and correlated with cumulative dose per kilogram of body weight.23PubMed Central. Reduced Chance of Hearing Loss Associated with Therapeutic Drug Monitoring of Aminoglycosides in the Treatment of Multidrug-Resistant Tuberculosis Keeping doses at or below certain thresholds, informed by blood level testing, appeared to preserve efficacy while limiting toxicity. The cumulative dose is really the key variable: more total drug exposure over time means more hearing damage, which is why shorter courses are safer than longer ones.
Drug-Resistant Tuberculosis and the Global Toll
The intersection of aminoglycosides and drug-resistant TB treatment deserves its own attention because it is where antibiotic ototoxicity causes the most widespread harm globally. Injectable aminoglycosides like amikacin and kanamycin were long a backbone of drug-resistant TB regimens, often administered daily for months. In a South African cohort of 379 adults being treated for drug-resistant TB with aminoglycoside-based regimens, 63% developed some level of hearing loss.24PubMed Central. Aminoglycoside-induced Hearing Loss Among Patients Being Treated for Drug-resistant Tuberculosis in South Africa: A Prediction Model Risk factors in that study included higher weekly aminoglycoside dose, HIV status with low CD4 count, age, low serum albumin, low body mass index, and pre-existing hearing loss.
This staggering rate has driven a major shift in TB treatment policy. In recent years, the World Health Organization updated its guidelines to recommend newer oral drugs like bedaquiline and linezolid in place of injectable aminoglycosides for many drug-resistant TB patients. The change was motivated in large part by the hearing loss burden. In many low- and middle-income countries where drug-resistant TB is most common, audiometric monitoring and hearing aids are not readily available, meaning patients who lose their hearing during treatment may have limited options for rehabilitation. The trade-off between curing a fatal disease and causing permanent hearing loss has been one of the more difficult dilemmas in global health.
Research into Otoprotective Strategies
Given that aminoglycosides remain essential drugs in many settings, researchers have been searching for compounds that could protect the inner ear without reducing the antibiotic’s infection-fighting ability. A recent scoping review identified three main strategies being explored. The first uses antioxidants like N-acetylcysteine (NAC), vitamin C, and various plant-derived compounds to neutralize the reactive oxygen species that drive hair cell death. The second aims to stabilize mitochondria, since much of the damage pathway runs through mitochondrial dysfunction. The third tries to physically block aminoglycosides from entering hair cells through the mechanotransduction channels that sit at the tips of hair cell stereocilia.25PubMed Central. Experimental and Clinical Approaches to Preventing Aminoglycoside-Induced Ototoxicity: A Scoping Review
In human studies, aspirin has the strongest and most reproducible evidence for protecting against gentamicin-induced hearing loss, while NAC has shown consistent benefit specifically in dialysis patients receiving aminoglycosides. Vitamin E, despite looking promising in animal experiments, has not shown clinically meaningful protection in randomized human trials.25PubMed Central. Experimental and Clinical Approaches to Preventing Aminoglycoside-Induced Ototoxicity: A Scoping Review None of these strategies are yet standard of care, and the evidence remains limited and somewhat inconsistent across different drugs and patient populations. The channel-blocking approach, using compounds like ORC-13661 that stop aminoglycosides from getting into hair cells in the first place, is conceptually appealing but still in early stages of development. For now, the most reliable prevention remains sensible dosing, drug level monitoring, serial audiometry, and avoiding unnecessary co-administration of other ototoxic agents.